Darbepoetin alfa

also known as ARANESP · darbepoetin · NESP · darbepoetin alpha · CKD-11101 · BCD-066 · Darbe · darbepoetin-α · +4 more

Developed for: anemia · chronic kidney disease · myelodysplastic syndrome · cancer · chronic renal failure syndrome · end stage renal failure · congestive heart failure · leukemia
+30 more
· anemia due to chronic disorder · breast cancer · kidney disorder · acute myocardial infarction · B-cell chronic lymphocytic leukemia · cardiac ventricle disorder · cirrhosis of liver · diffuse large B-cell lymphoma · breast neoplasm · chronic obstructive pulmonary disease · cognitive disorder · colorectal cancer · female breast carcinoma · heart failure · hematopoietic and lymphoid cell neoplasm · iron deficiency anemia · lung neoplasm · neurodevelopmental disorder · perinatal asphyxia · plasma cell myeloma · small cell lung carcinoma · spinal cord ischemia · stroke disorder · aregenerative anemia · brain hypoxia - ischemia · fetal erythroblastosis · hemolytic disease of fetus and newborn, RH-induced · myocardial infarction · Rh isoimmunization · traumatic brain injury
Investigated by: Amgen · National Cancer Institute (NCI) · Biocad · Chong Kun Dang Pharmaceutical · Kyowa Kirin, Inc. · Seoul National University Hospital
+73 more
· Astellas Pharma Inc · Brigham and Women's Hospital · Bristol-Myers Squibb · Dana-Farber Cancer Institute · GlaxoSmithKline · Institute of Liver and Biliary Sciences, India · Kyntra Bio · M.D. Anderson Cancer Center · Mayo Clinic · Nanogen Pharmaceutical Biotechnology Joint Stock Company · The Hospital for Sick Children · University of New Mexico · Vietstar Biomedical Research · Alberta Children's Hospital · Assistance Publique - Hôpitaux de Paris · Beth Israel Deaconess Medical Center · CLINICAL RESEARCH VIET NAM SKILL TRAINING AND CONSULTING COMPANY LIMITED · Celgene Corporation · Chinese University of Hong Kong · Clinical Research Consultants, Inc. · Clinical Research Viet Nam Skill Training And Consultant Company Limited · Dong-A ST Co., Ltd. · Enhanced Emirates Limited · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Fundacion Clinic per a la Recerca Biomédica · Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon · GBG Forschungs GmbH · Gangnam Severance Hospital · German CLL Study Group · Groupe Francophone des Myelodysplasies · Hallym University Medical Center · Harold J. Burstein, MD, PhD · Heinrich-Heine University, Duesseldorf · Herning Hospital · Hoffmann-La Roche · Hospital Authority, Hong Kong · Indian Council of Medical Research · Institut Claudius Regaud · Intermountain Health Care, Inc. · Jonsson Comprehensive Cancer Center · Kirin Pharmaceutical (Asia) CO., LTD · Kosin University Gospel Hospital · Lowell General Hospital · Lymphoma Study Association · MEDPHASE CLINICAL RESEARCH CONSULTANT COMPANY LIMITED · Massachusetts General Hospital · MedProve Inc · Memorial Sloan Kettering Cancer Center · Mirhashemi, Ramin, M.D. · NICHD Neonatal Research Network · National Heart, Lung, and Blood Institute (NHLBI) · North Shore Medical Center · Ortho Biotech Products, L.P. · Peter L Greenberg · Pharmacia · Rigshospitalet, Denmark · Roche Pharma AG · Rufaida Mazahir · Showa University School of Medicine · Thrasher Research Fund · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · UMC Utrecht · University Hospital Tuebingen · University Hospital, Basel, Switzerland · University Hospital, Montpellier · University of Aarhus · University of Colorado, Denver · University of Pennsylvania · University of Utah · University of Washington · Wake Forest University Health Sciences · Yale University · Zydus Lifesciences Limited

Regulatory milestones approvals, filings & regulatory actions · 9 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (7)	US (FDA)	ARANESP	—	2002-07-19 – 2019-01-30	fda.gov ↗
Approved	US (FDA)	ARANESP	—	2001-09-17	fda.gov ↗
Approved	EU (EMA)	Aranesp	—	2001-06-08	europa.eu ↗

Trials 123 · started per year

today

EU approved 2001

US approved 2001

199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 17 trials
Phase 1	NCT05636891	Sep 2021 → Nov 2022	chronic kidney disease	Nanogen Pharmaceutical Biotechnology Joint Stock Company	Completed	No outcome recorded
Phase 1	NCT03693950	Mar → Jul 2017	—	Biocad	Completed	No outcome recorded
Phase 1	NCT01428154	Apr → Nov 2016	anemia, chronic kidney disease	Amgen	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1	NCT02241200	Aug → Nov 2014	anemia	Dong-A ST Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02506881	Mar 2013 → Jul 2014	—	Biocad	Completed	No outcome recorded
Phase 1	NCT01685671	Oct → Dec 2012	anemia	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT01684605	Oct → Nov 2012	anemia	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT00117247	Jun 2002 → Jul 2004	anemia, congestive heart failure	Amgen	Completed	No outcome recorded
Phase 1/2	NCT00230321	Feb 2002 → Nov 2007	myelodysplastic syndrome	Peter L Greenberg	Completed	No outcome recorded
Phase 1/2	NCT00540384	Jul 1999 → Mar 2002	anemia, cancer	Amgen	Completed	No outcome recorded
Phase 239 trials · 2 met primary · 5 missed
Phase 2	NCT07096297	Dec 2025 → Aug 2030 expected	myelodysplastic syndrome	Yale University	Recruiting	No outcome recorded
Phase 2	NCT05340465	Nov 2022 → Jan 2027 expected	disorder of iron metabolism and transport, iron deficiency anemia	University of Washington	Recruiting	No outcome recorded
Phase 2	NCT03457701	Jul 2019 → Jul 2022	anemia	GlaxoSmithKline	Completed	Missed primary
Phase 2	NCT03071861	Dec 2017 → Dec 2019	perinatal asphyxia	University of New Mexico	Completed	No outcome recorded
Phase 2	NCT03171818	Jul 2017 → Dec 2024	stroke disorder	UMC Utrecht	Unknown	No outcome recorded
Phase 2	NCT01977573	Oct 2013 → May 2015	anemia	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT02890602	Sep 2012 → Nov 2017	diffuse large B-cell lymphoma	Kosin University Gospel Hospital	Completed	No outcome recorded
Phase 2	NCT01497145	Dec 2011 → Feb 2014	myelodysplastic syndrome	Kyowa Kirin, Inc.	Completed	No outcome recorded
Phase 2	NCT01222195	Feb 2008 → Jul 2010	leukemia	M.D. Anderson Cancer Center	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00647998	Jan 2008 → Jul 2010	spinal cord ischemia	University of Pennsylvania	Completed	Missed primary
Phase 2	NCT00416624	May 2007 → Jun 2009	anemia, leukemia, lymphoproliferative syndrome, plasma cell neoplasm +1	Mayo Clinic	Completed	No outcome recorded
Phase 2	NCT00401544	Dec 2006 → Dec 2007	anemia, neoplasm	Amgen	Completed	No outcome recorded
Phase 2	NCT00443339	Dec 2006 → Jul 2008	myelodysplastic syndrome	Groupe Francophone des Myelodysplasies	Unknown	No outcome recorded
Phase 2	NCT00398047	Sep 2006 → Sep 2009	leukemia, myelodysplastic syndrome	Wake Forest University Health Sciences	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00359840	Jul 2006 → Sep 2007	anemia	Kyowa Kirin, Inc.	Completed	No outcome recorded
Phase 2	NCT00334737	Jun 2006 → Dec 2013	—	University of New Mexico	Completed	No outcome recorded
Phase 2	NCT01039350	Feb 2006 → Jul 2008	myelodysplastic syndrome	Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00239239	Aug 2005 → Jan 2007	anemia, cancer	Amgen	Completed	No outcome recorded
Phase 2	NCT00144131	Aug 2005 → ?	anemia, cancer	Amgen	Completed	Met primary
Phase 2	NCT00095277	Oct 2004 → ?	anemia	Amgen	Completed	No outcome recorded
Phase 2	NCT00095264	Oct 2004 → ?	myelodysplastic syndrome	Amgen	Completed	No outcome recorded
Phase 2	NCT00210002	Nov 2003 → Apr 2006	anemia, neoplasm	Institut Claudius Regaud	Terminated	No outcome recorded
Phase 2	NCT00086086	Aug 2003 → ?	anemia, congestive heart failure	Amgen	Completed	No outcome recorded
Phase 2	NCT00146562	Jul 2003 → May 2007	breast cancer	Harold J. Burstein, MD, PhD	Completed	No outcome recorded
Phase 2	NCT00204633	Jul 2003 → Dec 2008	dysgerminoma	University Hospital Tuebingen	Completed	No outcome recorded
Phase 2	NCT00058422	Feb 2003 → Nov 2019	lymphoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00120705	Nov 2002 → Sep 2003	anemia, neoplasm	Amgen	Completed	Met primary
Phase 2	NCT00121030	Oct 2002 → Dec 2003	anemia, female reproductive organ cancer	Amgen	Completed	No outcome recorded
Phase 2	NCT00120679	Oct 2002 → Dec 2003	anemia, non-small cell lung carcinoma	Amgen	Completed	No outcome recorded
Phase 2	NCT00120692	Oct 2002 → Dec 2003	anemia, breast cancer	Amgen	Completed	No outcome recorded
Phase 2	NCT00049985	Jul 2002 → ?	anemia, heart failure	Amgen	Completed	Missed primary
Phase 2	NCT00989092	May 2002 → Jan 2004	anemia due to chronic disorder, carcinoma	Amgen	Terminated	Missed primary Stop: Enrollment
Phase 2	NCT00527215	Mar 2002 → Oct 2003	—	Amgen	Completed	No outcome recorded
Phase 2	NCT00035607	Dec 2001 → Dec 2002	anemia, neoplasm	Amgen	Completed	No outcome recorded
Phase 2	NCT00540696	Sep 2001 → Jun 2003	anemia, neoplasm	Amgen	Completed	No outcome recorded
Phase 2	NCT00039884	Sep 2001 → Mar 2003	anemia, cervical cancer	Mirhashemi, Ramin, M.D.	Unknown	No outcome recorded
Phase 2	NCT00526929	May 2000 → Feb 2002	—	Amgen	Completed	No outcome recorded
Phase 2	NCT00036023	—	B-cell chronic lymphocytic leukemia, breast neoplasm, lung neoplasm, plasma cell myeloma	Amgen	Completed	Missed primary
Phase 2	NCT00111462	—	anemia, cancer	Amgen	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT00501917	Mar 2007 → Feb 2010	acute myocardial infarction	Seoul National University Hospital	Unknown	No outcome recorded
Phase 2/3	NCT00381836	Oct 2006 → Feb 2007	anemia, prostate neoplasm	University of Aarhus	Terminated	No outcome recorded
Phase 346 trials · 10 met primary · 10 missed
Phase 3	NCT07169643	Nov 2025 → Dec 2026 expected	—	Fundacion Clinic per a la Recerca Biomédica	Recruiting	No outcome recorded
Phase 3	NCT05768997	Mar 2023 → Dec 2025	anemia	Hallym University Medical Center	Unknown	No outcome recorded
Phase 3	NCT05585645	Aug 2019 → Nov 2022	anemia, chronic kidney disease	Nanogen Pharmaceutical Biotechnology Joint Stock Company	Completed	No outcome recorded
Phase 3	NCT04012957	Jul 2019 → Aug 2021	anemia, chronic kidney disease	Zydus Lifesciences Limited	Completed	No outcome recorded
Phase 3	NCT03169881	Sep 2017 → Dec 2022	cognitive disorder, neurodevelopmental disorder	NICHD Neonatal Research Network	Completed	Missed primary
Phase 3	NCT02988973	Jan 2017 → Sep 2019	chronic kidney disease	Astellas Pharma Inc	Completed	Met primary
Phase 3	NCT02952092	Nov 2016 → Mar 2018	chronic kidney disease	Astellas Pharma Inc	Completed	Met primary
Phase 3	NCT02506868	Aug 2015 → Jan 2017	anemia, end stage renal failure	Biocad	Completed	No outcome recorded
Phase 3	NCT03431623	May 2015 → Feb 2017	anemia due to chronic disorder	Chong Kun Dang Pharmaceutical	Completed	Met primary
Phase 3	NCT02175277	Jun 2014 → Mar 2017	myelodysplastic syndrome	Amgen	Completed	No outcome recorded
Phase 3	NCT01652872	Jul 2012 → Oct 2017	—	Amgen	Completed	Missed primary
Phase 3	NCT01581073	Feb 2012 → Dec 2017	chronic kidney disease, diabetes mellitus	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	Completed	Missed primary
Phase 3	NCT01362140	Dec 2011 → Feb 2015	myelodysplastic syndrome	Amgen	Completed	Met primary
Phase 3	NCT00858364	Jul 2009 → Jun 2017	anemia, non-small cell lung carcinoma	Amgen	Terminated	Met primary
Phase 3	NCT01043991	Dec 2008 → Jul 2010	acute myocardial infarction	University Hospital, Montpellier	Completed	Missed primary
Phase 3	NCT00579046	Nov 2008 → Oct 2009	anemia, chronic obstructive pulmonary disease	Assistance Publique - Hôpitaux de Paris	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT00436748	Sep 2008 → Mar 2014	anemia, chronic kidney disease	Amgen	Terminated	No outcome recorded
Phase 3	NCT00534456	Jan → Oct 2007	anemia, cardiac ventricle disorder, congestive heart failure	Amgen	Terminated	No outcome recorded
Phase 3	NCT00358215	Jun 2006 → Oct 2012	anemia, cardiac ventricle disorder, congestive heart failure	Amgen	Completed	Missed primary
Phase 3	NCT00436995	Apr 2006 → Jan 2007	chronic kidney disease	Amgen	Completed	No outcome recorded
Phase 3	NCT00344409	Mar 2006 → May 2007	anemia	Kyowa Kirin, Inc.	Completed	No outcome recorded
Phase 3	NCT00661999	Jan 2006 → Mar 2009	anemia, cancer of unknown primary site, leukemia, lymphoproliferative syndrome +2	Mayo Clinic	Completed	Missed primary
Phase 3	NCT00116701	May 2005 → ?	chronic kidney disease	Amgen	Completed	No outcome recorded
Phase 3	NCT00213291	Apr → Sep 2005	chronic renal failure syndrome	The Hospital for Sick Children	Completed	No outcome recorded
Phase 3	NCT00121602	Mar → Oct 2005	anemia, chronic kidney disease	Amgen	Completed	No outcome recorded
Phase 3	NCT00135317	Nov 2004 → ?	cancer	Amgen	Completed	No outcome recorded
Phase 3	NCT00096915	Oct 2004 → Nov 2005	chronic kidney disease	Amgen	Completed	No outcome recorded
Phase 3	NCT00093977	Oct 2004 → Jan 2007	chronic kidney disease	Amgen	Completed	No outcome recorded
Phase 3	NCT00281892	Sep 2004 → May 2008	B-cell chronic lymphocytic leukemia, anemia	German CLL Study Group	Completed	No outcome recorded
Phase 3	NCT00115167	Aug 2004 → Jan 2007	anemia, cancer	Amgen	Completed	Missed primary
Phase 3	NCT00112008	May 2004 → Mar 2005	chronic kidney disease	Amgen	Completed	No outcome recorded
Phase 3	NCT00091858	Apr 2004 → Oct 2006	anemia, cancer	Amgen	Completed	Missed primary
Phase 3	NCT00111098	Mar 2004 → Nov 2005	kidney disorder	Amgen	Completed	No outcome recorded
Phase 3	NCT00110955	Feb 2004 → Mar 2005	anemia, neoplasm	Amgen	Completed	Met primary
Phase 3	NCT00144755	Dec 2003 → Dec 2012	diffuse large B-cell lymphoma	Lymphoma Study Association	Completed	Missed primary
Phase 3	NCT00070382	Aug → Nov 2003	anemia, leukemia, lymphoproliferative syndrome, plasma cell neoplasm +1	Jonsson Comprehensive Cancer Center	Completed	Met primary
Phase 3	NCT00111137	Feb → Nov 2003	cancer	Amgen	Completed	No outcome recorded
Phase 3	NCT00117624	Dec 2002 → Dec 2003	anemia	Amgen	Completed	Met primary
Phase 3	NCT00119613	Dec 2002 → Jan 2007	small cell lung carcinoma	Amgen	Completed	Mixed
Phase 3	NCT00119587	Aug 2002 → Sep 2003	anemia	Amgen	Completed	No outcome recorded
Phase 3	NCT00544232	Aug 2002 → Sep 2006	breast cancer	GBG Forschungs GmbH	Completed	Missed primary
Phase 3	NCT00038064	Jan 2002 → Oct 2003	anemia, neoplasm	Amgen	Completed	No outcome recorded
Phase 3	NCT00527137	Aug 2000 → Nov 2004	end stage renal failure	Amgen	Completed	Met primary
Phase 3	NCT03776032	Sep 1999 → Nov 2000	anemia	Amgen	Completed	No outcome recorded
Phase 3	NCT00148421	—	anemia	Amgen	Completed	Met primary
Phase 3	NCT00124098	—	chronic kidney disease	Amgen	Completed	No outcome recorded

Phase 417 trials · 2 met primary
Phase 4	NCT07523646	May 2026 → Apr 2028 expected	anemia, infective endocarditis	Rigshospitalet, Denmark	Recruiting	No outcome recorded
Phase 4	NCT07025460	Dec 2019 → Oct 2024 overdue	chronic kidney disease	Gangnam Severance Hospital	Active not recruiting	No outcome recorded
Phase 4	NCT04959578	Feb 2018 → Jan 2019	anemia due to chronic disorder	Rufaida Mazahir	Completed	Met primary
Phase 4	NCT01306409	Jan → Jul 2011	anemia	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 4	NCT00773513	Dec 2008 → Jul 2017	anemia due to chronic disorder	Hoffmann-La Roche	Completed	Met primary
Phase 4	NCT00117039	Jan 2004 → Apr 2005	anemia, neoplasm	Amgen	Completed	No outcome recorded
Phase 4	NCT00122720	Jun 2003 → Jan 2006	colorectal cancer	Herning Hospital	Completed	No outcome recorded
Phase 4	NCT00315484	Feb 2003 → Oct 2004	anemia	Ortho Biotech Products, L.P.	Completed	No outcome recorded
Phase 4	NCT00117117	Sep 2002 → Dec 2003	anemia	Amgen	Completed	No outcome recorded
Phase 4	NCT00369733	May 2002 → Mar 2004	chronic renal failure syndrome, end stage renal failure	Amgen	Completed	No outcome recorded
Phase 4	NCT00111995	May 2002 → ?	anemia, chronic renal failure syndrome	Amgen	Completed	No outcome recorded
Phase 4	NCT00369772	Feb 2002 → May 2004	chronic renal failure syndrome, end stage renal failure	Amgen	Completed	No outcome recorded
Phase 4	NCT00368901	Jan 2002 → Mar 2004	chronic renal failure syndrome, end stage renal failure	Amgen	Completed	No outcome recorded
Phase 4	NCT00117130	—	kidney disorder	Amgen	Completed	No outcome recorded
Phase 4	NCT00117078	—	kidney disorder	Amgen	Completed	No outcome recorded
Phase 4	NCT00117065	—	anemia	Amgen	Completed	No outcome recorded
Phase 4	NCT00117104	—	end stage renal failure	Amgen	Completed	No outcome recorded

Phase not applicable9 trials · 1 missed
—	NCT07568574	Mar 2026 → May 2028 expected	—	Enhanced Emirates Limited	Enrolling by invitation	No outcome recorded
—	NCT07131280	Sep 2025 → Jul 2031 expected	cirrhosis of liver	Institute of Liver and Biliary Sciences, India	Not yet recruiting	No outcome recorded
—	NCT07002827	Jun 2025 → Dec 2026 expected	cirrhosis of liver	Institute of Liver and Biliary Sciences, India	Recruiting	No outcome recorded
—	NCT00907608	Dec 2007 → May 2009	anemia, chronic kidney disease, diabetes mellitus	Chinese University of Hong Kong	Terminated	No outcome recorded Stop: Enrollment
—	NCT00355407	Jun 2006 → Aug 2007	hematopoietic and lymphoid cell neoplasm	Dana-Farber Cancer Institute	Completed	No outcome recorded
—	NCT00563446	Jul 2005 → May 2006	anemia, chronic renal failure syndrome	Hospital Authority, Hong Kong	Completed	No outcome recorded
—	NCT00309920	Jan 2004 → ?	female breast carcinoma	Heinrich-Heine University, Duesseldorf	Unknown	No outcome recorded
—	NCT00283621	Jun 2003 → Apr 2006	sarcoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
—	NCT00117234	Sep 2002 → Jul 2004	anemia, congestive heart failure	Amgen	Completed	Missed primary
Comparator or background therapy72 trials
Phase 1	NCT03992066 Background	May 2019 → May 2020	anemia due to chronic disorder	Akebia Therapeutics	Completed	No outcome recorded
Phase 1	NCT02731469 Comparator	Jun 2016 → Mar 2017	—	Biocad	Completed	No outcome recorded
Phase 1	NCT03542916 Comparator	Oct → Nov 2014	—	HK inno.N Corporation	Completed	No outcome recorded
Phase 1	NCT01363934 Comparator	Jun 2011 → Jul 2012	—	Green Cross Corporation	Completed	No outcome recorded
Phase 1/2	NCT06917950 Comparator	Apr → Oct 2025 overdue	end stage renal failure, mixed anxiety and depressive disorder	Mansoura University	Recruiting	No outcome recorded
Phase 1/2	NCT06903559 Comparator	Apr → Oct 2025 overdue	cardiovascular disorder, chronic renal failure syndrome, end stage renal failure, protein-energy malnutrition	Mansoura University	Recruiting	No outcome recorded
Phase 1/2	NCT04798339 Background	Mar 2021 → May 2025 overdue	myelodysplastic syndrome	H. Lee Moffitt Cancer Center and Research Institute	Active not recruiting	No outcome recorded
Phase 1/2	NCT01471015 Comparator	Sep 2012 → Jan 2014	brain hypoxia - ischemia	University of Utah	Completed	No outcome recorded
Phase 2	NCT07854561 Background	Aug 2026 → Feb 2027 expected	anemia due to chronic disorder	Chinese University of Hong Kong	Recruiting	No outcome recorded
Phase 2	NCT05265325 Comparator	May 2023 → Feb 2024	anemia	Kind Pharmaceuticals LLC	Completed	No outcome recorded
Phase 2	NCT04432662 Comparator	May 2021 → Sep 2024	—	Imperial College London	Unknown	No outcome recorded
Phase 2	NCT03810911 Comparator	Jan 2021 → Dec 2024	anemia, chronic kidney disease, hypertensive disorder	VA Office of Research and Development	Terminated	No outcome recorded
Phase 2	NCT03446612 Comparator	Jan → May 2019	anemia	GlaxoSmithKline	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT02055482 Comparator	Jun 2014 → Nov 2016	anemia, chronic kidney disease	Bayer	Completed	No outcome recorded
Phase 2	NCT02044653 Comparator	Apr 2014 → Apr 2017	anemia, chronic kidney disease	Genexine, Inc.	Completed	No outcome recorded
Phase 2	NCT02021409 Comparator	Jan 2014 → Oct 2015	anemia, chronic kidney disease	Bayer	Completed	No outcome recorded
Phase 2	NCT01888445 Comparator	Mar 2013 → Sep 2014	anemia due to chronic disorder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 2	NCT00968617 Comparator	Nov 2009 → Apr 2010	anemia, chronic kidney disease	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 2	NCT01538771 Comparator	Nov 2009 → Sep 2012	myocardial infarction	Seoul National University Bundang Hospital	Completed	No outcome recorded
Phase 2	NCT00375869 Comparator	Nov 2006 → Dec 2009	traumatic brain injury	Royal Alexandra Hospital	Completed	No outcome recorded
Phase 2	NCT00386152 Comparator	Nov 2006 → Mar 2008	anemia, cancer	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Terminated	No outcome recorded Stop: Business
Phase 2	NCT00327535 Comparator	May 2006 → May 2007	anemia	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT00261313 Background	Dec 2005 → Jun 2007	breast cancer	Amgen	Completed	No outcome recorded
Phase 2	NCT00077311 Background	Aug 2004 → Jul 2006	anemia, chemotherapy-induced toxicity, lung cancer, neutropenia	Alliance for Clinical Trials in Oncology	Completed	Missed primary
Phase 2	NCT00245895 Comparator	Apr 2003 → Feb 2005	anemia, prostate cancer	University of Washington	Completed	No outcome recorded
Phase 2/3	NCT03104426 Comparator	Oct 2017 → Aug 2020	Rh isoimmunization, fetal erythroblastosis, hemolytic disease of fetus and newborn, RH-induced	Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research	Unknown	No outcome recorded
Phase 2/3	NCT00234143 Comparator	Oct 2004 → ?	myelodysplastic syndrome	St. Bartholomew's Hospital	Unknown	No outcome recorded
Phase 3	NCT07300111 Comparator	Dec 2025 → May 2027 expected	anemia	Qilu Pharmaceutical Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 3	NCT06520826 Comparator	Nov 2024 → Jun 2026 overdue	anemia due to chronic disorder	USRC Kidney Research	Active not recruiting	Met primary
Phase 3	NCT06466785 Comparator	Jan 2024 → Jun 2027 expected	anemia due to chronic disorder	Genexine, Inc.	Recruiting	No outcome recorded
Phase 3	NCT04313153 Comparator	May 2020 → Nov 2021	anemia	Akebia Therapeutics	Completed	Mixed
Phase 3	NCT04027517 Comparator	Jan 2019 → Feb 2021	anemia due to chronic disorder	JW Pharmaceutical	Completed	No outcome recorded
Phase 3	NCT03543657 Comparator	Jun 2018 → Aug 2019	anemia, chronic kidney disease	Bayer	Completed	No outcome recorded
Phase 3	NCT03439137 Comparator	Feb → Dec 2018	anemia due to chronic disorder	Tanabe Pharma Corporation	Completed	Met primary
Phase 3	NCT03350347 Comparator	Dec 2017 → Jul 2019	anemia, chronic kidney disease	Bayer	Completed	No outcome recorded
Phase 3	NCT03350321 Comparator	Dec 2017 → May 2019	anemia, chronic kidney disease	Bayer	Completed	No outcome recorded
Phase 3	NCT03329196 Comparator	Oct 2017 → Jan 2019	anemia	Tanabe Pharma Corporation	Completed	Met primary
Phase 3	NCT03242967 Comparator	Aug 2017 → Feb 2018	anemia, chronic kidney disease	Akebia Therapeutics	Withdrawn	No outcome recorded
Phase 3	NCT03029208 Comparator	May 2017 → Sep 2020	anemia	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT02969655 Comparator	Nov 2016 → Jul 2018	anemia	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT02879305 Comparator	Sep 2016 → Nov 2020	allergic bronchopulmonary aspergillosis, anemia	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT02876835 Comparator	Sep 2016 → Apr 2021	anemia	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02912494 Comparator	Sep 2016 → Sep 2017	anemia	Kissei Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02892149 Comparator	Aug 2016 → Jan 2020	anemia, chronic kidney disease	Akebia Therapeutics	Completed	Met primary
Phase 3	NCT02865850 Comparator	Jul 2016 → Jan 2020	anemia, end stage renal failure	Akebia Therapeutics	Completed	Met primary
Phase 3	NCT02680574 Comparator	Feb 2016 → Jun 2020	anemia, chronic kidney disease	Akebia Therapeutics	Completed	Met primary
Phase 3	NCT02648347 Comparator	Dec 2015 → Jun 2020	anemia, chronic kidney disease	Akebia Therapeutics	Completed	No outcome recorded
Phase 3	NCT03428594 Comparator	Jun 2015 → Jun 2017	anemia due to chronic disorder	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 3	NCT02278341 Comparator	Nov 2014 → Jun 2017	anemia, end stage renal failure	Astellas Pharma Europe B.V.	Completed	Met primary
Phase 3	NCT02021318 Comparator	Mar 2014 → Mar 2018	aregenerative anemia	Astellas Pharma Europe B.V.	Completed	Met primary
Phase 3	NCT00925587 Comparator	Jun 2009 → Apr 2012	anemia, chronic kidney disease	Amgen	Completed	No outcome recorded
Phase 3	NCT00717821 Comparator	Aug 2008 → Jul 2011	anemia	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00605345 Comparator	Dec 2007 → Jul 2009	anemia	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00559273 Comparator	Dec 2007 → Oct 2009	anemia due to chronic disorder	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00598442 Comparator	Nov 2007 → Jul 2009	anemia, chronic renal failure syndrome	Affymax	Completed	Met primary
Phase 3	NCT00598273 Comparator	Oct 2007 → Mar 2009	anemia, chronic renal failure syndrome	Affymax	Completed	Met primary
Phase 3	NCT00442702 Comparator	Sep 2007 → Aug 2010	anemia	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00454246 Comparator	Apr 2007 → Feb 2008	anemia	Hoffmann-La Roche	Terminated	No outcome recorded Stop: Business
Phase 3	NCT00394953 Comparator	Dec 2006 → Nov 2008	anemia	Hoffmann-La Roche	Completed	Met primary
Phase 3	NCT00364845 Comparator	Sep 2006 → Dec 2008	anemia, chronic kidney disease	Amgen	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00090753 Comparator	Oct 2004 → Dec 2009	anemia	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00093015 Comparator	Aug 2004 → Mar 2009	anemia, chronic kidney disease, type 2 diabetes mellitus	Amgen	Completed	No outcome recorded
Phase 3	NCT00081471 Comparator	Jun 2004 → Jul 2006	anemia	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00077766 Comparator	Mar 2004 → Aug 2005	anemia	Hoffmann-La Roche	Completed	Met primary
Phase 3	NCT00118638 Comparator	Mar → Dec 2004	anemia, neoplasm	Amgen	Completed	No outcome recorded
Phase 4	NCT05864261 Comparator	May → Aug 2023	anemia	Yi Fang	Completed	No outcome recorded
Phase 4	NCT01506947 Background	May 2012 → Apr 2016	end stage renal failure, secondary hyperparathyroidism	AbbVie	Completed	No outcome recorded
Phase 4	NCT02049346 Comparator	Mar 2012 → Apr 2013	anemia due to chronic disorder	Hamad Medical Corporation	Completed	No outcome recorded
Phase 4	NCT02817555 Comparator	Sep 2010 → May 2013	anemia, chronic kidney disease	Andrea L Woodland	Completed	No outcome recorded
Phase 4	NCT00377481 Comparator	Sep 2006 → Jun 2007	anemia	Hoffmann-La Roche	Completed	No outcome recorded
Phase 4	NCT00153868 Comparator	Oct 2003 → Aug 2007	anemia, cancer	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
—	NCT01666301 Comparator	Feb 2010 → Apr 2012	—	Ospedale Regionale di Locarno	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 13

Date	Issuer	Release
2025-11-06	Akebia Therapeutics	Results Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs akebia.com ↗ The presentation entitled, “Win-Odds Analysis of Deaths and Hospitalization in Patients taking Vadadustat or Darbepoetin Alfa for CKD-Related Anemia Undergoing Dialysis,” demonstrated favorable and statistically significant effects of Vafseo relative to the erythropoiesis-stimulating agent (ESA) darbepoetin alfa on the composite endpoint of death or hospitalization.
2025-06-04	Akebia Therapeutics	Results Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology akebia.com ↗ Data from the pre-specified analyses for the U.S. patient subgroup demonstrate that among patients with DD-CKD, safety and efficacy of vadadustat and darbepoetin alfa in the U.S. and outside the U.S. were similar.
2022-04-25	Zydus Lifesciences Limited	Results Zydus announces publication of DREAM-ND and DREAM-D Phase 3 trials of Desidustat in American Journal of Nephrology zyduslife.com ↗ the mean baseline haemoglobin levels was 8.92 g/dL which improved to 10.77 g/dL, which met prespecified non-inferiority of Desidustat to Darbepoetin as per protocol.
2021-04-28	Akebia Therapeutics	Results New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease akebia.com ↗ Vadadustat, as compared with darbepoetin alfa, met the prespecified noninferiority criterion for hematologic efficacy but not the prespecified noninferiority criterion for cardiovascular safety.
2020-06-08	Astellas Pharma Inc	Results Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease astellas.com ↗ Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease
2020-05-22	Chong Kun Dang Pharmaceutical	Regulatory 종근당, 빈혈치료제 바이오시밀러 ‘네스벨’ 日 제조판매 승인 ckdpharm.com ↗ 종근당 ( 대표 김영주 ) 은 일본 후생노동성으로부터 세계 최초 2 세대 빈혈치료제 바이오시밀러 ‘ 네스벨 ’ 의 일본 내 제조판매 승인을 획득했다고 24 일 밝혔다 .
2019-11-09	Akebia Therapeutics	Results Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease akebia.com ↗ The difference in mean hemoglobin (Hb) was -0.26 g/dL (95% CI -0.50, -0.02 g/dL), achieving the pre-specified non-inferiority criterion of -0.75 g/dL.
2019-09-23	Dong-A ST Co., Ltd.	Regulatory 동아ST, SKK에 라이센싱 아웃한 다베포에틴-알파 바이오시밀러 ‘DA-3880’ 일본 제조판매 승인 획득 donga-st.com ↗ 동아에스티(대표이사 회장 엄대식)는 일본 파트너사인 삼화화학연구소(Sanwa Kagaku Kenkyusho, SKK, 대표이사 사장 하타 카츠미)가 지속형 적혈구조혈자극제인 다베포에틴-알파(Darbepoetin-α) 바이오시밀러 ‘DA-3880’의 일본 내 제조판매 승인을 후생노동성으로부터 획득했다고 23일 밝혔다.
2018-10-01	Dong-A ST Co., Ltd.	Regulatory Dong-A ST submits application for authorization to market DA-3880, licensed out to Sanwa Kagaku Kenk donga-st.com ↗ Sanwa Kagaku Kenkyusho (SKK, President Hata Katsumi) had submitted its application for authorization to market DA-3880, a biosimilar of ‘Darbepoetin-α’, a sustained erythropoiesis-stimulating agent, to the Ministry of Health, Labor and Welfare of Japan.
2018-08-16	Kyowa Kirin, Inc.	Regulatory Kyowa Hakko Kirin Announces Approval of Darbepoetin Alfa Injection Syringe[KKF] in Japan kyowakirin.com ↗ "Darbepoetin Alfa Injection Syringe [KKF]," which has just been approved in Japan, is an "Authorized version*1" of NESP®.
2016-02-15	Amgen	Results Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS) amgen.com ↗ Amgen (NASDAQ:AMGN) today announced that the randomized, double-blind, placebo-controlled Phase 3 Aranesp ® (darbepoetin alfa) ARCADE trial met its primary endpoint of reducing the incidence of red blood cell transfusions in anemic patients with low and intermediate-1 risk MDS at the end of the blinded 25-week study period.
2014-12-18	Kyowa Kirin, Inc.	Regulatory Approval for Additional Indication of NESP® for Anemia with Myelodysplastic Syndromes in Japan kyowakirin.com ↗ Kyowa Hakko Kirin Co, Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") today announced that NESP® Injection Plastic Syringe (NESP®), a long-acting erythropoiesis stimulating agent, has been approved in Japan for an additional indication of anemia with myelodysplastic syndromes*1.
2014-03-31	Kyowa Kirin, Inc.	Regulatory Application Seeking Approval for Additional Indication of NESP® for Anemia with Myelodysplastic Syndrome in Japan kyowakirin.com ↗ Kyowa Hakko Kirin Co, Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") today announced that it has filed an application to Japan's Ministry of Health, Labour and Welfare (MHLW) seeking approval for additional indication of NESP® Injection Plastic Syringe (NESP®) for anemia with myelodysplastic syndrome.

All press releases naming this drug 14 releases

Date	Issuer	Release
2025-11-06	Akebia Therapeutics	Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs akebia.com ↗
2025-06-04	Akebia Therapeutics	Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology akebia.com ↗
2022-04-25	Zydus Lifesciences Limited	Zydus announces publication of DREAM-ND and DREAM-D Phase 3 trials of Desidustat in American Journal of Nephrology zyduslife.com ↗
2021-04-28	Akebia Therapeutics	New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease akebia.com ↗
2020-06-08	Astellas Pharma Inc	Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease astellas.com ↗
2020-05-22	Chong Kun Dang Pharmaceutical	종근당, 빈혈치료제 바이오시밀러 ‘네스벨’ 日 제조판매 승인 ckdpharm.com ↗
2019-11-09	Akebia Therapeutics	Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease akebia.com ↗
2019-09-23	Dong-A ST Co., Ltd.	동아ST, SKK에 라이센싱 아웃한 다베포에틴-알파 바이오시밀러 ‘DA-3880’ 일본 제조판매 승인 획득 donga-st.com ↗
2019-07-29	Kyowa Kirin, Inc.	Kyowa Kirin Announces Launch of Darbepoetin Alfa Injection Syringe[KKF] in Japan kyowakirin.com ↗
2018-10-01	Dong-A ST Co., Ltd.	Dong-A ST submits application for authorization to market DA-3880, licensed out to Sanwa Kagaku Kenk donga-st.com ↗
2018-08-16	Kyowa Kirin, Inc.	Kyowa Hakko Kirin Announces Approval of Darbepoetin Alfa Injection Syringe[KKF] in Japan kyowakirin.com ↗
2016-02-15	Amgen	Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS) amgen.com ↗
2014-12-18	Kyowa Kirin, Inc.	Approval for Additional Indication of NESP® for Anemia with Myelodysplastic Syndromes in Japan kyowakirin.com ↗
2014-03-31	Kyowa Kirin, Inc.	Application Seeking Approval for Additional Indication of NESP® for Anemia with Myelodysplastic Syndrome in Japan kyowakirin.com ↗

Evidence & citations 16 cited values

Every value below carries the sentence it was read from. 205 sources stand behind the page.

Field	Value	Cited text
Known as	darbepoetin alfa	“This study will compare the efficacy (non-inferiority) of darbepoetin alfa (Aranesp®) extended dose schedule administration (EDS) versus darbepoetin alfa administered once per...” NCT00144131 ↗ 166 “The present study was designed to determine whether or not darbepoetin alfa is non-inferior to recombinant human erythropoietin in the treatment of anemia in children with...” NCT04959578 ↗ “A Randomized, Blinding, Single-dose, Positive-drug Parallel Control Study to Compare the Pharmacokinetics Following Administration of JT1801 and Darbepoetin Alfa Injection...” NCT05864261 ↗ “A Phase 3 Multi-center, Randomized, Open-label, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Non-dialysis Chronic Kidney...” NCT02988973 ↗ “rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.” NCT03457701 ↗ “the test (CJ-40001) and reference (NESP®) versions of darbepoetin alfa following a single subcutaneous (SC) or intravenous (IV) administration in healthy male subjects.” PMID 30506495 ↗ Feb 2019 “Intervention in patients who prior has not been treated with EPO, will begin with 150 μg Darbepoetin alfa with weekly measurements of hemoglobin.” NCT07523646 ↗ “Patients receive azacitidine subcutaneously (SC) or intra-venous (IV) on days 1-5 (week 1) and darbepoetin alfa* SC on day 8 (week 2).” NCT00398047 ↗ “Darbepoetin alfa is an erythropoiesis-stimulating agent (ESA) approved for treating chemotherapy-induced anaemia.” PMID 18540943 ↗ Jun 2008 “epoetin alfa if they were receiving hemodialysis or darbepoetin alfa if they were receiving peritoneal dialysis” PMID 34739194 ↗ Nov 2021 “Darbepoetin alfa will be administered every 3 weeks (21 days), at a starting dose of 300 ug (Dose Level 0).” NCT07096297 ↗ Show 156 more sources
Known as	ARANESP	“This study will compare the efficacy (non-inferiority) of darbepoetin alfa (Aranesp®) extended dose schedule administration (EDS) versus darbepoetin alfa administered once per...” NCT00144131 ↗ 29 “Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.” NCT05585645 ↗ “A Multicenter Study Evaluating Once Every Other Week Subcutaneous Administration of Aranesp (Darbepoetin Alfa) in Subjects With Anemia of Chronic Renal Insufficiency (CRI)” NCT00369772 ↗ “Darbepoetin (Aranesp) pre-filled syringes 500 mcg and filgrastim (Neupogen) pre-filled syringes 300 mcg will be supplied by Amgen (UK)and provided free of charge.” NCT00234143 ↗ “Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer” NCT00381836 ↗ “500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks” NCT00386152 ↗ “Epoetin alfa (EPOGEN), Methoxy polyethylene glycol-epoetin beta (Mircera), or Darbepoetin alfa (Aranesp)” NCT06520826 ↗ “A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)” NCT02241200 ↗ “Study drug: Darbepoetin alfa (Aranesp) 500 microg every two weeks subcutaneously during 12 weeks” NCT00443339 ↗ “In the United States, darbepoetin alfa (Aranesp) is often used to” PMID 16478746 ↗ Feb 2006 “darbepoetin alfa (ARANESP; 200 mcg every other week)” NCT00315484 ↗ Show 19 more sources
Known as	BCD-066	“BCD-066 is a darbepoetin alfa.” NCT03693950 ↗ 1 “BCD-066” NCT02506868 ↗
Known as	CKD-11101	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03428594 ↗ 3 NCT03431623 ↗ NCT01685671 ↗ NCT01684605 ↗
Known as	Darbe	“Darbepoetin alfa (Darbe), a recombinant human erythropoietin (EPO)-derived molecule” NCT01471015 ↗
Known as	darbepoetin	“The purpose of this study is to see if the treatment of severely brain injured patients with darbepoetin (a long acting form of erythropoietin) will be safe, and will reduce...” NCT00375869 ↗ 15 “Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care,...” NCT01977573 ↗ “Standard of care treatment for renal anemia, typically involving administration of erythropoiesis-stimulating agents (ESAs, e.g., epoetin, darbepoetin) and/or intravenous iron...” NCT06903559 ↗ “Standard of care treatment for renal anemia, typically involving administration of erythropoiesis-stimulating agents (ESAs, e.g., epoetin, darbepoetin) and/or intravenous iron...” NCT06917950 ↗ “erythropoietic-stimulating agent, darbepoetin (Darbe), plus a slow-release intravenous (IV) iron preparation” PMID 41430711 ↗ Dec 2025 NCT01306409 ↗ NCT02055482 ↗ NCT07169643 ↗ NCT00443339 ↗ NCT00501917 ↗ NCT07131280 ↗ Show 5 more sources
Known as	darbepoetin alpha	“Darbepoetin alpha (300 microg) or placebo was administered once per week for 4 weeks then every 3 weeks for up to six cycles of chemotherapy (carboplatin plus etoposide or...” PMID 18467726 ↗ May 2008 6 “To determine whether or not Darbepoetin alpha (DA) was non-inferior to recombinant human erythropoietin (rHuEPO) in the treatment of anemia in children with chronic kidney...” PMID 36220980 ↗ Oct 2022 “AIM: To evaluate the ability of intracoronary administration of darbepoetin-alpha (DA) at the very onset of the reperfusion, to decrease infarct size (IS).” PMID 23582675 ↗ Feb 2013 “Darbepoetin alpha (Aranesp®) is produced by gene-technology in Chinese Hamster Cells (CHO-K1).” NCT00381836 ↗ “Darbepoetin alpha administered QM was well tolerated in study subjects.” PMID 17116009 ↗ Dec 2006 “Darbepoetin Alpha (10 mcg/kg) IV x2 doses following cooling therapy.” NCT04432662 ↗ “darbepoetin alpha (DA) for treating patients” PMID 18227526 ↗ Jan 2008
Known as	darbepoetin-α	“darbepoetin-α (ARANESP®; Jeil-Kirin Pharm., Korea)” PMID 23506972 ↗ Mar 2013
Known as	Darbepoietin alfa	“Darbepoietin alfa will be administered to these patients.” NCT02890602 ↗
Known as	EPO	“Growth factors {like GCSF, darbepoetin (EPO) have shown survival benefits with improve liver repair and regeneration” NCT07131280 ↗
Known as	KRN321	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01497145 ↗
Known as	NESP	“A Randomized, Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) Using Fixed and Weight-Based Dosing for the Treatment of Anemia in Subjects...” NCT00111462 ↗ 13 “A Randomized, Blinding, Single-dose, Positive-drug Parallel Control Study to Compare the Pharmacokinetics Following Administration of JT1801 and Darbepoetin Alfa Injection...” NCT05864261 ↗ “A Randomized, Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulation Protein, NESP) and rHuEPO for the Treatment of Anemia in Subjects With Non-Myeloid...” NCT00038064 ↗ “An Open-label, Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa (NESP)” NCT00540696 ↗ “Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)” NCT00540384 ↗ “Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP)” NCT00035607 ↗ “Darbepoetin alfa, (also referred to as Aranesp or NESP)” NCT00245895 ↗ “darbepoetin alfa (NESP)” NCT00526929 ↗ NCT03428594 ↗ NCT00039884 ↗ NCT01685671 ↗ Show 3 more sources
Known as	Novel Erythropoiesis Stimulation Protein	“A Randomized, Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulation Protein, NESP) and rHuEPO for the Treatment of Anemia in Subjects With Non-Myeloid...” NCT00038064 ↗
Action	Activate	“including activation of the EPO receptor” NCT01471015 ↗
Modality	Protein / enzyme biologic	“Darbepoetin alfa is a recombinant protein that stimulates the production of red blood cells.” NCT00035607 ↗
Route	Subcutaneous	“Subcutaneous (SC) injection of darbepoetin alfa” NCT00035607 ↗